We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M Turnover 22.92%
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+13.84%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$372M
AUM Growth
+$4.91M
Cap. Flow
-$21.9M
Cap. Flow %
-5.89%
Top 10 Hldgs %
47.82%
Holding
97
New
8
Increased
10
Reduced
34
Closed
10
Avg Time Held
2.3 years
Top 10 Avg Time Held
1.6 years
Top 20 Avg Time Held
2 years

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$3.96M
2
MDWD icon
MediWound
MDWD
+$2.57M
3
SYRS icon
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.16M
4
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.4M
5
KURA icon
Kura Oncology
KURA
+$1.37M

Top Sells

Rank Stock Value
1
KRTX icon
Karuna Therapeutics, Inc. Common Stock
KRTX
+$6.71M
2
NTUS
Natus Medical Inc
NTUS
+$4.71M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.96M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$3.65M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 84.3%
2 Miscellaneous 15.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$44.9M 12.07%
566,000
-47,000
-8% -$3.96M
2022 Q1
2 quarters
STXS icon
2
Stereotaxis
STXS
$105M
$24.6M 6.62%
13,680,554
– –
2013 Q2
37 quarters
BPMC icon
3
DELISTED
Blueprint Medicines
BPMC
$17.2M 4.63%
261,235
-45
-0% -$2.89K
2016 Q4
23 quarters
BHVN icon
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$16.6M 4.48%
110,100
– –
2018 Q2
17 quarters
ASND icon
5
Ascendis Pharma A/S
ASND
$14.9B
$14M 3.77%
135,712
-3,500
-3% -$332K
2021 Q4
3 quarters
XENE icon
6
Xenon Pharmaceuticals
XENE
$3.28B
$13.5M 3.64%
375,223
-63,400
-14% -$2.28M
2015 Q3
28 quarters
ACET icon
7
Adicet Bio
ACET
$45.8M
$13.3M 3.58%
58,485
– –
2020 Q3
8 quarters
FATE icon
8
Fate Therapeutics
FATE
$232M
$12.1M 3.25%
539,940
-11,000
-2% -$318K
2019 Q2
13 quarters
IBB icon
9
iShares Biotechnology ETF
IBB
$10.4B
$12M 3.22%
102,500
– –
2016 Q4
23 quarters
RVMD icon
10
Revolution Medicines
RVMD
$41.5B
$9.46M 2.54%
479,785
+180,000
+60% +$3.96M
2020 Q4
7 quarters
CYTK icon
11
Cytokinetics
CYTK
$8.82B
$8.91M 2.4%
183,995
-27,500
-13% -$1.32M
2021 Q3
4 quarters
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.21B
$8.54M 2.3%
355,487
-15,500
-4% -$348K
2020 Q2
9 quarters
NBIX icon
13
Neurocrine Biosciences
NBIX
$13.8B
$8.51M 2.29%
80,155
-2,500
-3% -$254K
2016 Q1
26 quarters
IDYA icon
14
IDEAYA Biosciences
IDYA
$3.27B
$8.04M 2.16%
538,561
-10,000
-2% -$130K
2020 Q3
8 quarters
EWTX icon
15
Edgewise Therapeutics
EWTX
$4.02B
$7.69M 2.07%
781,112
+85,153
+12% +$860K
2022 Q1
2 quarters
NRIX icon
16
Nurix Therapeutics
NRIX
$2.59B
$7.38M 1.99%
566,695
– –
2021 Q1
6 quarters
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.2M 1.94%
401,476
-1,000
-0.2% -$13.1K
2020 Q2
9 quarters
SAGE icon
18
DELISTED
Sage Therapeutics
SAGE
$7.06M 1.9%
180,306
– –
2017 Q4
19 quarters
KRTX icon
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.5M 1.75%
28,886
-33,167
-53% -$6.71M
2020 Q1
10 quarters
CBAY icon
20
DELISTED
Cymabay Therapeutics
CBAY
$5.96M 1.6%
1,703,235
-84,334
-5% -$303K
2021 Q1
6 quarters
DXCM icon
21
DexCom
DXCM
$31.5B
$5.84M 1.57%
72,552
– –
2017 Q3
20 quarters
MRUS icon
22
DELISTED
Merus
MRUS
$5.55M 1.49%
276,893
+14,002
+5% +$334K
2021 Q1
6 quarters
MORF icon
23
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.53M 1.49%
195,467
– –
2020 Q4
7 quarters
ALEC icon
24
Alector
ALEC
$210M
$5.04M 1.35%
532,438
-20,000
-4% -$216K
2021 Q3
4 quarters
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5M 1.35%
71,600
-8,000
-10% -$592K
2022 Q1
2 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, DAFNA Capital Management held 97 positions worth $372M, up 1.3% from $367M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $21.9M in Q3 2022, closing 10 positions and reducing 34 holdings. Its most notable exit was Natus Medical Inc, an estimated $4.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in MediWound worth $1.99M.

  • DAFNA Capital Management's largest Q3 2022 buy was MediWound: 204,082 shares worth $1.99M.
  • DAFNA Capital Management added most to Revolution Medicines in Q3 2022, an estimated $3.96M increase.
  • DAFNA Capital Management's biggest Q3 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $6.71M.
  • DAFNA Capital Management fully exited Natus Medical Inc in Q3 2022, selling an estimated $4.71M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $372M portfolio in Q3 2022.
  • DAFNA Capital Management opened 8 new positions and closed 10 in Q3 2022.
  • DAFNA Capital Management's portfolio value rose 1.3% quarter-over-quarter to $372M.

Based on DAFNA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.